DLA Piper announced that Abrar Hussain has joined the firm’s Emerging Growth and Venture Capital practice as a partner in Palo Alto, further expanding its capabilities across life sciences, venture capital, and the broader innovation economy.
Hussain brings more than 25 years of experience spanning the investment funds, biotechnology, and financial services sectors. His practice includes advising clients on fund formation, fundraising, operations, limited partnership negotiations, portfolio company support, complex mergers and acquisitions, initial public offerings, licensing arrangements, and cross-border transactions. He most recently served as General Counsel and Chief Compliance Officer at Samsara BioCapital, a hybrid public and private biotechnology investment firm with approximately $2.1 billion in assets under management and more than 100 portfolio companies.
According to DLA Piper, Hussain’s investor-side perspective enhances the firm’s ability to advise life sciences and technology clients on strategic transactions and growth opportunities. His arrival also continues the firm’s investment in its West Coast corporate practice. Over the past 18 months, DLA Piper has added partners Josh Seidenfeld, John Hutar, Frances Mosley, Brady Berg, Ken Funahashi, Sarah Chambless, and Michael Dorf.
DLA Piper’s Emerging Growth and Venture Capital practice comprises more than 200 lawyers serving emerging companies and venture capital firms across high-growth sectors, including technology, healthcare, life sciences, and financial services. During the last three years, the firm completed more than 2,100 financings globally with an aggregate value exceeding $80 billion. PitchBook ranks DLA Piper among the most active law firms globally by venture capital deal volume.
KEY QUOTES:
“In today’s market, clients need counsel with sharp judgment, deep transactional experience, and a sophisticated understanding of the venture capital and life sciences ecosystem. Abrar’s investor side experience further supports our ability to help life sciences and tech clients navigate complex challenges, capitalize on opportunities, and execute on their most important strategic objectives.”
Andrew Gilbert, Global Co-Chair Of The Corporate Practice, DLA Piper
